Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scandinavian ChemoTech’s TSE technology gives hope to horses suffering from sarcoids

Today the ESVONC congress in Syracuse, Italy, opens. In a poster, presented at the congress, the Tumour Specific Electroporation - TSE™ treatment of a horse is outlined and described as showing outstanding results.The author of this poster is DVM (Doctor in Veterinary Medicine) Majbritt M E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg. The title of the poster is: “Treatment of equine sarcoids using intratumoral Bleomycin in combination with Tumour Specific Electroporation - TSE™” and describes the outstanding

Mental Health Awareness Month: How 9-to-5 Workers Can Improve Their Mental Health

Kasparas Aleknavičius, MD, Head of Medical Affairs at digital health and wellness accelerator Kilo Health, together with his team, has been researching the topic of mental health and sedentary lifestyle correlation. They seek to educate 9-to-5 workers to pursue a physically and mentally healthy life even if the circumstances can be aggravating.Over 80% of all US jobs are predominantly sedentary, and 8.4% of all US adults have faced a major depressive episode at least once in their lives. Various studies outline the correlations between lack of physical activity and emotional well-being. The

SAGA-PROPOSAL FROM THE NOMINATION COMMITTEE OF SAGA PURE ASA FOR THE ANNUAL GENERAL MEETING 30 MAY 2022

Reference is made to the stock exchange notice from Saga Pure ASA dated 9 May 2022, where the Company called for the Annual General Meeting for Saga Pure ASA to be held on 30 May 2022. Enclosed is the Recommendation from the Nomination Committee of Saga Pure ASA for the annual general meeting. For additional information, please contact: Espen Lundaas, CFO, +47 92 43 14 17 About Saga Pure ASA | www.sagapure.com Saga Pure ASA is an investment company focusing on opportunities within renewable energy, hydrogen, circular economy and CO2-reduction.

Time Series: unique feature for market analysis and data-based investments

Leading B2B provider of structured web data DomainCrawler announced the release of a new feature for its Domain Research platform – Time Series. This functionality will allow users to track the use of website technologies over a certain time range, gaining insights regarding the popularity of a certain application on the Internet.  DomainCrawler specializes in collecting and structuring raw web data. The company possesses a database of over 1.4 billion domain names

Sinch resolves on an in-kind issue of shares to the sellers of Pathwire

Stockholm, Sweden – 26 May 2022 – Sinch AB (publ) (the “Company” or “Sinch”), a global leader in cloud communications for mobile customer engagement, today announces that the board of directors, in accordance with what was communicated on 7 December 2021, has resolved on an in-kind share issue of 25.5 million shares to the sellers of Pathwire. On 30 September 2021, Sinch disclosed that it had entered into an agreement to acquire Pathwire and the acquisition was completed on 7 December 2021. In addition to the cash consideration, Sinch shall issue an aggregate of 51 million shares in the

Ingka Group approaching 500 companies to accelerate labour integration of refugees

Ingka Group announced today that it will approach 500 businesses with the aim to inspire the private sector to accelerate the labor integration of refugees. Speaking at the World Economic Forum in Davos, Ingka Group CEO Jesper Brodin said the company was also sharing their lessons learned in a toolkit to support and inspire more businesses to open pathways to decent work.“The human tragedy in Ukraine has put a spotlight on a global refugee crisis that has been building for years,” Brodin said. “While we know that short-term emergency relief is important, and we’re doing what we can, our

Read original

Capital increase in TORM due to exercise of Restricted Share Units as part of TORM’s incentive program

TORM plc (“TORM”) increases its share capital by 102,214 A-shares (corresponding to a nominal value of USD 1,022.14) as a result of the exercise of a corresponding number of Restricted Share Units.   The capital increase is carried out without any pre-emption rights for existing shareholders or others. All 102,214 new shares are subscribed for in cash. 74,436 of the new shares have been subscribed for at DKK 64.3 per A-share and the remaining 27,778 new shares have been subscribed for at DKK 53.5 per A-share. All with a nominal value of USD 0.01 each.   The new shares are

IFS Named A Leader in IDC MarketScape for Worldwide SaaS and Cloud-Enabled Manufacturing ERP in 2022

London, UK, May 26 2022 – IFS , the global cloud enterprise software company, today announced that it is positioned in the Leaders category in IDC MarketScape: Worldwide SaaS and Cloud-Enabled Manufacturing ERP Applications 2022 Vendor Assessment (doc #US49047922, May 2022) . The company attributes its continued growth and success to its deep industry expertise, innovative and flexible IFS Cloud solution, and service management expertise.The IDC MarketScape study provides an

Etrion Releases First Quarter 2022 Results.

May 26, 2022, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”, and, together with its subsidiaries, the “Group”) released today its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three months ended March 31, 2022. Q1-2022 HIGHLIGHTS · Etrion closed the first quarter of2022 with an unrestricted cash balance of US$18.1 million and a positive working capital of US$17.1 million. · The Company sold all the solar assets in 2021 and is not developing any new project in the first quarter 2022.

Pexip Holding ASA – Grant of Share Options to Senior Executives and Employee Share Options Exercise

The Board of Directors (“The Board”) of Pexip Holding ASA (“Pexip” or “The Company”) has on May 25, 2022 granted a total of 1,150,000 share options, equal to 1.1% of total shares issued in the Company, to members of the Company’s Senior Leadership Team. The exercise price is NOK 17.28 per share, which is equal to the volume-weighted average traded on Oslo Børs in the past seven days before the award, and the options are exercisable after December 31, 2024.  All options expire on December 31, 2026 and are conditional upon employment at time of exercise and the Company’s performance. 1/3 of

OPITO and NOWI announce partnership to support skills and safety in the US offshore wind sector

OPITO, the leading global safety and skills organisation for the energy industry, and the National Offshore Wind Institute (NOWI), based at Bristol Community College in Massachusetts, have today (Thursday 28[th]  April) signed a Memorandum of Understanding (MoU) which will support thousands of new jobs in the growing US offshore wind energy sector.Under the terms of the MoU, OPITO will work with NOWI to optimise workforce development and provide skills and safety training for the emerging New Bedford Port cluster in South Massachusetts and its pipeline of offshore wind projects. The U.S

Africa Oil Announces the Receipt of Prime Dividend

VANCOUVER, BC, May 25, 2022 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“AOI”, “Africa Oil” or “the Company”) is pleased to announce that it has received a dividend from Prime Oil and Gas Cooperatief UA (“Prime”). The Company has a 50% shareholding in Prime. Prime has distributed a $50.0 million dividend with a net payment to Africa Oil of $25.0 million related to its shareholding. This is the second Prime dividend distributed this year with Africa Oil having received an aggregate amount of $125.0 million. Since acquiring its 50% interest in Prime for a cash

ShaMaran Announces Successful Rights Offering Details

VANCOUVER, BC, May 25, 2022 /CNW/ - ShaMaran Petroleum Corp. (“ShaMaran” or the “Company”) (SNM: TSX-V and Nasdaq First North Growth Market (Sweden)) is pleased to announce further details following the Company’s news release of May 20, 2022 with respect to the Company’s rights offering (the ”Rights Offering”) that was oversubscribed by the Company’s shareholders and no call on the standby commitment of Nemesia S.à.r.l.1 was required.  ShaMaran has issued 558,242,414 common shares of the Company (the "Common Shares") at the price of CAD $0.06825 (SEK 0.52) per Common Share being the maximum

Eco Wave Power Announces Submission of Formal Application for Delisting from Nasdaq First North Growth Market in Stockholm as Part of U.S. Focus

ADSs Will Continue to Trade on the Nasdaq Capital Market in the U.S.Stockholm, Sweden – May 25, 2022 – Eco Wave Power Global AB (publ) (Nasdaq: WAVE, Nasdaq First North: ECOWVE) (“Eco Wave Power” or the “Company”), a leader in the production of clean electricity from ocean and sea waves, today announced that it has submitted a formal application of delisting from Nasdaq First North Growth Market Sweden (“Nasdaq First North”). The Company submitted the application 90 days after announcing its intention to delist via a press release on February 25, 2022. The Company hereby clarifies

Wicket Gaming AB (publ) carries out a directed issue of shares of approximately SEK 5 million and raises a loan of SEK 15 million

Wicket Gaming AB (publ) (“Wicket Gaming” or the “Company”) has, with the support of the authorization from the Annual General Meeting on March 16, 2021, completed a directed issue of 277,778 shares (the “Directed Issue”) to a strategic investor. The subscription price amounted to SEK 18 per share, which corresponds to a discount of approximately 9 percent comparison to the closing price on May 24, 2022. The company will receive approximately SEK 5 million through the Directed Issue. In connection with the Directed Issue, the Board of Directors proposes, subject to the support of the

Nordea Bank Abp: Repurchase of own shares on 25.05.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares25.05.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 25.05.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number Weighted average Total cost, EUR* **venue (MIC of price / share, EUR* Code) shares **XSTO 154,392 9.55 1,473,997.60XHEL 106,601 9.60 1,023,881.28CEUX 206,292 9.58 1,976,984.55AQEU 26,088 9.60 250,459.91

Annual General Meeting held

The Annual General Meeting (AGM) of Bonheur ASA was held today, Wednesday 25 May 2022. All items on the agenda, which had been sent to Oslo Stock Exchange on 4 May 2022, were resolved in accordance with the corresponding proposals placed before the AGM. The Vice Chairman of the Shareholders' Committee, Einar Harboe, chaired the AGM. The Chairman of the Board, Fred. Olsen, was present. The Managing Director of Bonheur, Anette S. Olsen, and Bonheur's auditor, Øyvind Skorgevik from KPMG, were also present at the meeting. The AGM approved the financial statements and annual report of

Everfuel: Mandatory notification of trade by primary insider

Herning, Denmark, 25 May 2022 – Søren Eriksen, Chair of Board of Directors of Everfuel A/S, has today purchased 6,091 shares in Everfuel A/S at an average price of NOK 58,31 per share. Following this, Eriksen holds a total of 6,091 shares in Everfuel.  For additional information, please contact: Anders Bertelsen, CFO, +45 21 35 43 03, ab@everfuel.com About Everfuel | www.everfuel.com Everfuel is making green hydrogen for zero emission mobility commercially available across Europe, offering competitive all-inclusive hydrogen supply- and fueling solutions. We own and operate

Norway Royal Salmon ASA (NRS): CFO Ola Loe steps down

(Trondheim, 25 May 2022) Ola Loe steps down from his position as CFO of Norway Royal Salmon ASA ("NRS") after 13 years in the company. He will for a transitional period remain available for the board and management team of NRS. "Ola has done a solid job for NRS and he has played an important role in the development of the company since he took the position as CFO in 2009. I would like to thank Ola for his commitment and wish him the best of luck in the future, says Charles Høstlund  - Interim CEO in NRS. "NRS has had a fantastic development from 2009. From an annual harvest volume of

TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

Viken – 25th May, 2022 – A new study with TikoMed’s platform lead clinical drug candidate ILB®\,\[ ]provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The study was published in PLOS ONE today. In a Phase II study of ILB® administered to patients with ALS for five weeks, the progression of ALS was halted and/or reversed for all study participants assessed using the validated ALSFRS-R and Norris clincal rating scales that score a broad range of patient relevant

Endomines resolves on a directed issue of convertibles to LDA Capital Limited

Endomines AB (publ), Stock Exchange Release 25 May 2022 at 18:00 CEST   The Board of Directors of Endomines AB (publ) ("Endomines" or the "Company") has, based on the authorisation granted by the Annual General Meeting on 10 June 2021, resolved on a directed issue of convertibles with a total nominal amount of EUR 600,000 (corresponding to SEK 6,288,720[1]) to LDA Capital Limited ("LDA") (the “Directed Issue”), providing total issue proceeds of EUR 600,000.   The Directed Issue is carried out as part of the financing package which Endomines has entered into with LDA, which was

Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines

STOCKHOLM, SWEDEN – 25 May 2022: Modus Therapeutics Holding AB, a biopharma company focused on the clinical development of its proprietary asset sevuparin for the treatment of sepsis/septic shock and other conditions with systemic inflammation, provides an update on its ongoing Phase 1b LPS-challenge study and its other clinical activities with sevuparin.Modus has observed that the ongoing effects of the Covid-19 pandemic throughout spring have slowed down enrolment for the Phase 1b trial, causing a delay to the anticipated timelines. This is largely attributed to subjects being unable to

There are no items matching the current filter
There are no more items matching the current filter
Back to top